CA 15-3 in patients with locoregional and metastatic breast carcinoma
- 15 December 1992
- Vol. 70 (12), 2831-2834
- https://doi.org/10.1002/1097-0142(19921215)70:12<2831::aid-cncr2820701218>3.0.co;2-8
Abstract
Background. The value of circulating CA 15-3 levels was assessed in 129 patients with recurrent breast carcinoma. Methods. Patients were divided into four subgroups, according to the following: Group A, locoregional recurrence alone; Group B, locoregional and subsequent systemic recurrence; Group C, combined locoregional and systemic recurrence; and Group D, differing sites of systemic disease. Results. One of 14 patients with locoregional disease alone had increased levels of CA 15-3 (> 25 U/ml). However, 96% of patients (22 of 23 patients) with combined local and systemic disease had increased tumor marker levels. The difference in CA 15-3 levels in patients with combined disease compared with patients with local disease alone was statistically significant (117.0 versus 17.5 U/ml, respectively; P < 0.02). Twenty-four patients with locoregional recurrence later had distant metastasis develop. In this group, patients with an increased CA 15-3 value had a significantly shorter lead time to the development of distant metastases compared with patients with normal tumor marker levels (20.8 ± 3.3 versus 10.3 k 2.7 months, respectively; P < 0.03). CA 15-3 values at diagnosis were increased in 88% of 115 patients with metastatic disease. There was no significant difference in CA 15-3 levels among metastases to lung, liver, and bone nor was there any difference between single and multiple sites of distant metastasis. CA 15-3 is an excellent marker for systemic recurrence of breast carcinoma. Conclusions. Increased levels and no clinical evidence of recurrence strongly indicate the presence of occult metastatic disease.Keywords
This publication has 8 references indexed in Scilit:
- Tumor marker kinetics in the monitoring of breast cancerCancer, 1990
- Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic diseaseCancer, 1989
- Value of CA 15:3 in the follow-up of breast cancer patientsBritish Journal of Cancer, 1987
- Carcinoembryonic antigen in breast cancer. Clinical reviewAmerican Journal Of Medicine, 1986
- Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.JCI Insight, 1985
- Monoclonal antibodies against human milk‐fat globule membranes detecting differentiation antigens of the mammary gland and its tumorsInternational Journal of Cancer, 1984
- Clinical correlation between CEA and breast cancerCancer, 1978
- Biological markers in breast carcinoma:III. Clinical correlations with carcinoembryonic antigenCancer, 1977